Notably, pan-cancer analysis shows that glioblastomas exhibit high levels of CD73 similar to tumors that have shown a promising response to anti-CD73 antibody therapy in early trials (e.g., NSCLC). The gene discussed is NT5E; the disease is glioblastoma.